top of page

Wide_PrimaryAlt3 Padding.png

Sisterhood Content brought to you by:

SF Healthcare Week: Alnylam CEO Yvonne Greenstreet discusses the launch of Amvuttra in ATTR-CM and the company's new 2030 ambitions | 01/13/26

About the show: Members of the Biotech CEO Sisterhood regularly interview women leaders in biotech about news, science, management topics and more. Tune in to hear from top leaders in biotech about topics that matter to the industry.

Editorial Board Members

About the Sisterhood

The Biotech CEO Sisterhood is a vibrant community dedicated to championing the success of women leaders in the biopharma industry. Rooted in a culture of mutual support and authenticity, the Sisterhood aims to inspire and uplift women while driving meaningful conversations and impact across the industry. As part of our commitment to nurturing the current and future generations of biotech leaders, the Sisterhood hosts summits, local events, and educational sessions. These programs encourage dialogue about the challenges facing women in biotech, share best practices, and enhance leadership effectiveness. Since its inception in 2022, the Biotech CEO Sisterhood has grown to 300+ members. To follow our progress and learn more, please follow us on LinkedIn.

Abigail Jenkins

Bio

Erika Smith

Bio

Grace Colón

Bio

Julia Owens

Bio

Luba Greenwood

Bio

Sheila Gujrathi

Bio

Episodes

Biotech CEO Sisterhood: Biotech company chair, director, and former CEO Paula Soteropoulos discusses learnings from her career and announces a new book she and her daughter wrote about women's health | 10/19/26

Paula Soteropoulos discusses learnings from her career and announces a new book she and her daughter wrote about women's health

Oxford, UK based OMass Therapeutics announced a $310M series C today, advancing its small molecule platform, including the lead MC2 (melanocortin-2) receptor antagonist that is in phase 1 | 10/15/26

OMass Therapeutics announced a $310M series C today, advancing its small molecule platform, including the lead MC2 antagonist

Biotech CEO Sisterhood: Former BIO CEO Rachel King describes her career and shares advice on what makes a successful biotech CEO | 09/03/26

Former BIO CEO Rachel King describes her career and shares advice on what makes a successful biotech CEO

Biotech CEO Sisterhood: Katherine Stueland describes joining GeneDx as a first time CEO during a turbulent time and reshaping it into a leader in genetic testing for rare disease diagnosis | 08/20/26

Katherine Stueland describes joining GeneDx as a first time CEO during a turbulent time and reshaping it into a leader in genetic testing for rare disease diagnosis

Biotech CEO Sisterhood: Amy Burroughs discusses the success of Terns Pharma and developing TERN-701 for CML, being acquired by Merck for $6.7 billion, and leadership learnings throughout her career | 08/06/26

Amy Burroughs discusses the success of Terns Pharma and developing TERN-701 for CML, being acquired by Merck for $6.7 billion, and leadership learnings throughout her career

Biotech CEO Sisterhood: Fresh off of a successful IPO. Avalyn Pharma CEO Lyn Baranowski describes the company's inhaled medicines platform, and shares her secrets to success as a leader | 07/21/26

Avalyn Pharma CEO Lyn Baranowski describes the company's inhaled medicines platform, and shares her secrets to success as a leader

BIO 2026: Vir's is scheduled to have its first phase 3 readout in Hepatitis Delta before the end of the year - they believe that their dual mechanism is the difference maker here | 06/24/26

BIO 2026: Vir is scheduled to have its first phase 3 readout in Hepatitis Delta before the end of the year

Recludix will have initial clinical data for its SH2 STAT6 soon (2H 2026) - while it already made waves via a big partnership, a positive profile in humans could signal that SH2's time has arrived

BIO 2026: Texas based Nanoscope Therapeutics is using optogenetics, or light to turn cells on or off, to try to restore vision for retinal conditions | 06/26/26

BIO 2026: Texas based Nanoscope Therapeutics is using optogenetics, or light to turn cells on or off, to try to restore vision for retinal conditions

BIO 2026: AltruBio believes that its PSGL-1, a T-cell checkpoint targeting antibody, could be a "ceiling raiser" in the I&I space | 06/25/26

BIO 2026: AltruBio believes that its PSGL-1, a T-cell checkpoint targeting antibody, could be a "ceiling raiser" in the I&I space

BIO 2026: COUR Pharma last week raised a $50M series B to progress its nanoparticle approach to reprogramming the immune system to treat type 1 diabetes | 06/24/26

BIO 2026: COUR Pharma last week raised a $50M series B to progress its nanoparticle approach to reprogramming the immune system to treat type 1 diabetes

EHA 2026: Caribou Biosciences CEO Rachel Haurwitz shares an EHA update on her company's CD19 and BCMA allogeneic CAR-T programs | 06/12/26

Caribou Biosciences CEO Rachel Haurwitz shares an EHA update on her company's CD19 and BCMA allogeneic CAR-T programs

ASCO 2026: Vir Biotechnology CEO Marianne De Backer discusses the company's masked T-cell engager platform, which recently earned the company a partnership with Astellas on PSMA | 05/30/26

Vir Biotechnology CEO Marianne De Backer discusses the company's masked T-cell engager platform, which recently earned the company a partnership with Astellas on PSMA

ASCO 2026: Bicara Therapeutics is presenting long-term follow up data at ASCO that it believes shows durability derived from choosing TGF-β with EGFR for its fusion protein in HPV negative head & neck | 05/31/26

Bicara Therapeutics is presenting long-term follow up data at ASCO that it believes shows durability derived from choosing TGF-β with EGFR for its fusion protein in HPV negative head & neck

ASGCT 2026: Barcelona based Integra Therapeutics believes its FiCAT gene writing platform can deliver a larger payload capacity and with more precision than with traditional viral vectors | 05/13/26

Integra Therapeutics believes its FiCAT gene writing platform can deliver a larger payload capacity and with more precision than with traditional viral vectors

ASGCT 2026: Siren Biotechnology recently has seen two INDs cleared for its AAV based gene therapy for oncology. Founder Nicole Paulk discusses how they are prepared to enter the clinic shortly | 05/13/26

Siren Biotechnology recently has seen two INDs cleared for its AAV based gene therapy for oncology. Founder Nicole Paulk discusses how they are prepared to enter the clinic shortly

SGCT 2026: Epicrispr Biotechnologies is already in the clinical with its epigenetic approach to genetic medicine. At ASGCT, it showed off how versatile this platform might be | 05/12/26

Epicrispr Biotechnologies is already in the clinic with its epigenetic approach to genetic medicine. At ASGCT, it showed off how versatile this platform might be

Barclays Miami: Recludix believes the time is right in science to drug SH2 domains. The company's lead programs target STAT6 and BTK | 03/10/26

Recludix believes the time is right in science to drug SH2 domains. The company's lead programs target STAT6 and BTK

Barclays Miami: Electra Therapeutics has taken a novel approach to target Signal Regulatory Proteins (SIRPs). It's in a pivotal for its first indication right now | 03/10/26

Electra Therapeutics has taken a novel approach to target Signal Regulatory Proteins (SIRPs). It's in a pivotal for its first indication right now

Ovid Therapeutics' new CEO Meg Alexander walks us through the company's lead programs in neurology | 02/02/26

Ovid Therapeutics' new CEO Meg Alexander walks us through the company's lead programs in neurology

Co-Founders Sheila Gujrathi and Julia Owens talk about the creation of the Biotech CEO Sisterhood and the new dimensions and next steps it is taking as an organization ahead | 02/02/26

Co-Founders Sheila Gujrathi and Julia Owens talk about the creation of the Biotech CEO Sisterhood and the new dimensions and next steps it is taking

01/14/26 - Sheila Gujrathi at JPM '26

01/14/26 - Julia Owens at JPM '26

01/14/26 - Elizabeth Tuck at JPM '26

Bluejay Therapeutics' CEO Keting Chu talks about what led to the the successful $620M+ acquisition of her company and its chronic hepatitis delta virus antibody by Mirum

Bluejay Therapeutics' CEO Keting Chu talks about what led to the the successful $620M+ acquisition of her company

01/14/26 - Abigail Jenkins at JPM '26

01/14/26 - Christine Ann Miller at JPM '26

01/14/26 - Shehnaaz Suliman

at JPM '26

SF Healthcare Week: CEO Heather Turner tells us about the neuropsychiatric diseases medicine that enabled LB Pharma to IPO in a tough market last year | 01/15/26

Heather Turner tells us about the neuropsychiatric diseases medicine that enabled LB Pharma to IPO in a tough market last year

SF Healthcare Week: Recursion's new CEO Najat Khan shares her vision for the company and for AI in biotech

Recursion's new CEO Najat Khan shares her vision for the company and for AI in biotech

Capricor CEO Linda Marbán discusses the eventful year the company had for its DMD treatment deramiocel, including the P3 HOPE-3 readout, and the regulatory filing and review ahead | 01/13/26

Capricor CEO Linda Marbán discusses the eventful year the company had for its DMD treatment, Deramiocel, including the P3 HOPE-3 readout, and the regulatory filing and review ahead

Biotech CEO Sisterhood: Kate Haviland discusses the success factors that led to the $9B+ acquisition of Blueprint Medicines, and the trend of biotech companies taking commercial assets further | 12/15/25

Kate Haviland discusses the success factors that led to the $9B+ acquisition of Blueprint Medicines, and the trend of biotech companies taking commercial assets further

Biotech CEO Sisterhood: EpiBone creates bones and cartilage grown from stem cells - Co-Founder and CEO Nina Tandon describes the creative thinking she has used to accelerate its availability | 12/11/25

EpiBone creates bones and cartilage grown from stem cells - Co-Founder and CEO Nina Tandon describes the creative thinking she has used to accelerate its availability

Biotech leader Sheila Gujrathi discusses her new book, The Mirror Effect, which she wrote for her younger self, today's peers, and the next generation of female leaders in business | 12/2/25

Biotech leader Sheila Gujrathi discusses her new book, The Mirror Effect, which she wrote for her younger self, today's peers, and the next generation of female leaders in business

Biotech CEO Sisterhood: Stealth BioTherapeutics' CEO Reenie McCarthy describes the fortitude and close relationship with a patient community that lead to the first approved therapy for Barth Syndrome | 11/13/25

Stealth BioTherapeutics' CEO Reenie McCarthy describes the fortitude and close relationship with a patient community that led to the first approved therapy for Barth Syndrome

Biotech CEO Sisterhood: Hanadie Yousef leads Juvena Therapeutics, a company is developing protein based therapeutics that are tissue restorative for muscle and metabolic diseases | 09/04/25

Hanadie Yousef leads Juvena Therapeutics, a company developing protein based therapeutics that are tissue restorative for muscle and metabolic diseases

Biotech CEO Sisterhood: Catherine Pickering is leading iOnctura, which is focused on solving the problem of cancer resistance both at the tumor and around its environment | 09/04/25

Catherine Pickering leads iOnctura, which is focused on solving cancer resistance both at the tumor and its environment

Biotech CEO Sisterhood: Sheila Gujrathi is an experienced leader in biotech, a co-founder of the Biotech CEO Sisterhood, and has a new book coming out next month | 09/04/25

Sheila Gujrathi is a leader, a co-founder of the Biotech CEO Sisterhood, and has a new book coming out next month

Biotech CEO Sisterhood: Stacy Blain is the Founder and CEO of Concarlo Therapeutics, which is the first company to target CDK4/6-driven cell proliferation and CDK2-driven resistance | 09/04/25

Stacy Blain is the Founder of Concarlo Therapeutics, which is the 1st company to target both CDK4/6 and CDK2

Biotech CEO Sisterhood: Catherine Sabatos-Peyton is running Larkspur Biosciences, a company targeting cancer cell fitness | 09/04/25

Catherine Sabatos-Peyton is leading Larkspur Biosciences, a company targeting cancer cell fitness

Biotech CEO Sisterhood: Kiran Mazumdar-Shaw, builder of India's leading biotech enterprise and a pioneer in the development of biologics and biosimilars, shares her story and learnings from business | 09/02/25

Kiran Mazumdar-Shaw on building India's leading biotech enterprise and learnings from her career in business

Biotech CEO Sisterhood: Ivana Liebisch on her career path, the successful sale of Vigil to Sanofi, moving quickly and decisively on decisions, and her thoughts on leadership | 08/19/25

Ivana Liebisch on her career path, the successful sale of Vigil to Sanofi, moving quickly and decisively on decisions, and her thoughts on leadership

Biotech CEO Sisterhood: Trevi Therapeutics' Co-Founder & CEO Jennifer Good on good communication and capital efficiency, and a unique internship program in life sciences | 08/06/25

Trevi Therapeutics' Co-Founder & CEO Jennifer Good on effective communication and capital efficiency, and a unique internship program in life sciences

Biotech CEO Sisterhood: As CEO, Sophie Kornowski sold Boston Pharmaceuticals to GSK earlier this year for up to $2 billion. She shares her thoughts on the biopharma business and on leadership | 07/18/25

As CEO, Sophie Kornowski sold Boston Pharmaceuticals to GSK earlier this year for up to $2 billion. She shares her thoughts on the biopharma business and leadership

Biotech CEO Sisterhood: Daré Bioscience's Founder & CEO Sabrina Johnson describes her company's mission to make women's health a priority | 05/06/25

Daré Bioscience's Founder & CEO Sabrina Johnson describes her company's mission to make women's health a priority

Biotech CEO Sisterhood: Named CEO of Acadia Pharmaceuticals in September, Catherine Owen Adams describes taking the leap from a career in 'pharma' to running an independent, commercial stage biotech | 04/22/25

Catherine Owen Adams describes taking the leap from a career in 'pharma' to running an independent, commercial stage biotech

Biotech CEO Sisterhood: X4 Pharmaceuticals' CEO Paula Ragan on her career and running a commercial stage company in the rare disease space | 04/08/25

X4 Pharmaceuticals' CEO Paula Ragan on her career and running a commercial stage company in the rare disease space

Biotech CEO Sisterhood: Gallop Oncology CEO Luba Greenwood on the importance of the Sisterhood, the Massachusetts life sciences ecosystem, and the work at Gallop | 03/27/25

Gallop Oncology CEO Luba Greenwood on the importance of the Sisterhood, the Massachusetts life sciences ecosystem, and Gallop's work

Biotech CEO Sisterhood: Alnylam CEO Yvonne Greenstreet on her career path, the importance of diversity of opinions, and leading Alnlyam into a critical phase of growth | 03/17/25

Alnylam CEO Yvonne Greenstreet on her career path, the importance of diversity of opinions, and leading Alnlyam into a critical phase of growth

Biotech CEO Sisterhood Vir's CEO Marianne De Backer describes her background and leadership style, and joining Vir as it experienced a road bump, but turning it into an opportunity via a key IO deal | 03/03/25

Marianne De Backer's background and leadership style, and executing a key IO deal at Vir at an important time

Biotech CEO Sisterhood: Serial entrepreneur Sheila Mikhail on overcoming obstacles and getting the job done, including multiple major buyouts in her own career | 02/18/25

Serial entrepreneur Sheila Mikhail on overcoming obstacles and getting the job done, including multiple major acquisitions in her own career

Biotech CEO Sisterhood: Avidity Biosciences' CEO Sarah Boyce discusses a leader's responsibility to address dysfunction and the importance of corporate culture | 02/04/25

Avidity Biosciences' CEO Sarah Boyce discusses a leader's responsibility to address dysfunction and the importance of corporate culture

Biotech CEO Sisterhood: Mary Lynne Hedley shares advice on board makeup, running board meetings, and other factors into having an effective board of directors | 01/21/25

Mary Lynne Hedley shares advice on board makeup, running meetings, and other factors into having an effective board of directors

Biotech CEO Sisterhood: A leadership series discussion on building an effective board, best practices for running meetings, hiring talent, and decision making | 01/06/24

A leadership series discussion on building an effective board, best practices for running meetings, hiring talent, and decision making

Biotech CEO Sisterhood: Heather Turner and Sheila Gujrathi discuss managing your board of directors effectively | 12/19/24

Heather Turner and Sheila Gujrathi discuss managing your board of directors effectively

Biotech CEO Sisterhood: Melinta Therapeutics CEO Christine Miller on expanding the company into the acute care business, improving employee satisfaction, and her leadership principles | 12/12/24

Melinta Therapeutics CEO Christine Miller on expanding the company into the acute care business, improving employee satisfaction, and her leadership principles

Biotech veteran Deborah Dunsire on trends in drug development, investments, regulation, and her advice on key skills for growing into position of leadership | 12/5/24

Deborah Dunsire on trends in drug development, investments, regulation, and her advice on key skills for growing into position of leadership

The Sisterhood in their own words

Pink on the Square at JPM '26

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsors

10x_Genomics_logo.svg.png

NYSE_logo_large_no reg_378x197 (1).png

Learn more about our sponsors

Sponsor Spotlight

Mispro is an AAALAC-accredited contract vivarium organization (CVO) offering a network of full-service vivarium rental lab facilities for preclinical in vivo rodent studies. Along with access to state-of-the-art lab spaces, Mispro supports its clients with comprehensive laboratory animal research services, including husbandry, veterinary, technical, and regulatory compliance oversight. With locations in all major U.S. biotech hubs, Mispro is committed to helping biosciences companies of all sizes and therapeutic indications achieve their research goals.

bottom of page